Abstract Methamphetamine (METH) is a stimulant drug that is toxic primarily to dopaminergic and serotonergic neurons and may lead to inflammatory changes in the brain. Additionally, the glutamatergic system is altered following METH exposure. Therefore, concentrations of brain glutamate+glutamine (GLX) were assessed during abstinence from chronic METH abuse. Twenty-five subjects with a history of METH dependence (age 31.8± 7.4 years, 14 women and 11 men) and 28 control subjects without a history of drug abuse (age 32.6±8.8 years, 14 women) were enrolled. Twelve of the METH subjects were followed and rescanned 5 months later. METH users had used the drug 5.9±1.7 times per week, for 109± 69 months, and had been abstinent for 2.1±3.0 months. GLX was measured in the basal ganglia and frontal gray and white matter, using proton magnetic resonance spectroscopy. While overall GLX concentrations at baseline were similar between METH and control subjects, METH users with less than or equal to 1 month of abstinence showed reduced frontal gray matter GLX ( p= 0.01). Time of abstinence correlated positively with GLX in frontal gray ( p<0.0001) and white matter ( p=0.03). After 5 months, changes in frontal gray matter GLX showed a trend to correlate inversely with the duration of abstinence ( p=0.07). Subjects with craving symptoms had lower frontal gray matter GLX than those without craving (−8%, p=0.05). These findings suggest dynamic abnormalities in brain GLX in recently abstinent METH users, with a depletion of the glutamatergic system in METH users within the first 2 months of abstinence and some normalization during prolonged abstinence. Since craving may contribute to relapse, medications that normalize GLX may minimize craving in METH users.
Introduction
Methamphetamine (METH) is an illicit stimulant drug commonly abused in the USA and worldwide. In addition to the acute effects of METH, such as the transient massive release of dopamine and glutamate (GLU), the drug has also been associated with long-lasting brain changes in humans. For instance, chronic but abstinent METH users were shown to have reduced dopamine transporters and altered glucose metabolism on positron emission tomography (PET; Volkow et al. 2001b ); however, these abnormalities appeared to normalize with prolonged abstinence in some brain regions (Volkow et al. 2001a; Wang et al. 2004 ). Other neurochemical changes in human METH users were found with proton magnetic resonance spectroscopy ( 1 H MRS), which can quantify various neuro-metabolites in the millimolar concentration range. Specifically, the neuronal marker N-acetyl-aspartate (NA) or NA-to-total creatine ratio (NA/Cr) may be decreased in abstinent METH abusers (Ernst et al. 2000; The neurotoxic effect of chronic METH exposure is further demonstrated by the associated neuroinflammatory responses, such as the activation of microglia, astroglia, and elevated mediators of inflammation including cytokines, chemokines, prostagladins, interleukins, as well as factors associated with oxidative stress (Asanuma et al. 2003 ; Thomas et al. 2004; Yamamoto and Bankson 2005) .
Recent research found that the effects of METH are related not only to dopamine and serotonin but also to other neurotransmitters such as GLU. For instance, the striatum of rats showed prolonged increases in extracellular GLU after METH administration (Nash and Yamamoto 1992) , and GLU might be an important contributor to oxidative stress-mediated neurotoxicity of METH (Yamamoto and Bankson 2005) . Cocaine is another psychostimulant that may affect the GLU system similarly to METH. In rats, low basal GLU concentrations in the nucleus accumbens was associated with the reinstatement of self-administration of cocaine, a model for relapse of cocaine use (Baker et al. 2003) . Furthermore, the reinstatement of cocaine selfadministration in cocaine-dependent rats was prevented by the administration of N-acetylcysteine, which stimulates the cystine/GLU exchanger and increases basal GLU concentrations (Cornish and Kalivas 2000) . A recent openlabeled study further showed that human cocaine users who were treated with N-acetylcysteine had longer retention during a 4-week medication trial and reduced cocaine usage (Mardikian et al. 2007 ). However, little is known about changes in the GLU system in human METH users.
Since the sum of GLU plus glutamine (GLX) can be evaluated by 1 H MRS, we assessed the effect of abstinence from chronic METH abuse on the brain concentrations of GLX in a cross-sectional sample of METH users and in a subset of these participants longitudinally after 5 months of abstinence. The GLX measured with 1 H MRS comprises both GLU and GLX from the intracellular and extracellular compartments, but these chemicals are largely sequestered intracellularly. Based on the preclinical studies, we hypothesized that GLX would be decreased in abstinent METH users, especially during early abstinence. Since craving for the drug is typically strong during early abstinence, we also expected that lower GLX levels may be associated with a greater craving for METH.
Materials and methods
A group of 25 subjects with a history of METH dependence (mean age 31.8±7.4 years, 11 men, 14 women) and 28 control subjects with no history of drug dependence (mean age 32.6±8.8 years, 14 men, 14 women) were screened and enrolled in the study. Each participant provided a written informed consent approved by our institutional review board prior to an extensive screening evaluation. The screening evaluation involved a detailed neuropsychiatric history and physical examination, screening blood tests, and urine toxicology screens and ensured that all METH users fulfilled the following study criteria: (1) age 18 to 50 years, (2) history of METH dependence according to the Diagnostic Statistical Manual IV criteria, (3) regular METH use for at least 12 months, at least five times per week, and at least 0.5 gram per day, (4) METH was the primary drug of choice, (5) no present or past alcohol abuse or dependence, (6) enrolled in a drug rehabilitation program, and (7) negative urine toxicology screen for illicit drugs (amphetamines, cocaine, marijuana, benzodiazepine, barbiturates, and opiates) at baseline assessment. Subjects in both METH user and control groups were excluded if they (1) were seropositive for human immunodeficiency virus-1, (2) had a history of head trauma with loss of consciousness for more than 30 min, (3) had a history of substance dependence including alcohol (except for METH in the METH user group and nicotine in either group), (4) had any chronic medical, neurological, or psychiatric illnesses (e.g., seizure disorders, depression, schizophrenia, hypertension, or diabetes), (5) were pregnant, or (6) had metallic implants contraindicated for the magnetic resonance studies. All healthy control subjects were on no medications. A detailed drug use history was also obtained from each subject for the most common illicit drugs, nicotine, and alcohol, using a standardized screening form. The total amount of lifetime exposure to METH was calculated by multiplying the average daily METH amount taken (in g/day) with the number of days per week METH was used, times the total time period (in weeks) of METH use.
All subjects underwent a baseline 1 H MRS study. Additionally, 1 H MRS was repeated 5 months after the baseline scan in 12 of the 25 abstinent METH abusers, using identical techniques and identical voxel locations. These 12 subjects were followed carefully as outpatients by study personnel and the staff at the rehabilitation center; the remaining 13 subjects were lost to follow-up. Craving was assessed by self-report on the day of the MRS examination, using a visual analog scale (VAS, 0-100; 100=strongest craving).
Localized 1 H MRS was performed on a 1.5-T GE scanner, using a quadrature head coil. Three voxels were evaluated in the medial frontal gray matter (anterior cingulate), frontal white matter, and in the basal ganglia ( Fig. 1 ; volume approximately 5-6 cm 3 ). The spatial localization of spectra was achieved using a point-resolved spectroscopy sequence (Bottomley 1987) with the gradient order optimized for minimizing artifacts in the frontal lobe (Ernst and Chang 1996) . Data were acquired at short echo time (TE=30ms), relatively long repetition time (3 s), and 128 averages. These parameters allow the measurement of coupled resonances, in particular GLX, and minimize the effects of T1 and T2 relaxation on metabolite values. Metabolite concentrations, including NA, myoinositol, and GLU+GLX, were determined relative to the magnetic resonance-visible brain water, using a well-validated technique that corrects for the T2 decay of the water signal and for the presence of cerebrospinal fluid (CSF) in each MRS voxel ). This was achieved by measuring the unsuppressed fully relaxed water signal in each voxel at ten different echo times and fitting the resulting water amplitudes to a double-exponential decay model. The spectra were processed with a well-validated semiautomatic program ) that involved a waterattenuation filter, mild apodization (0.5 Hz), zero filling, and DC baseline correction (determined from data points around 2.75 ppm). Peak areas were estimated by fitting a Lorentzian to the four major metabolite peak and by automatic integration of the β-γ-GLX signals between 2.2 and 2.4 ppm. Peak areas were then referenced to the brain water signal from the T2 fit to determine metabolite concentrations corrected for the percentage of CSF in each voxel.
Statistical analyses were performed in StatView (version 5.0.1) and SAS (both SAS Institute, Cary, NC, USA). Comparisons of GLX concentrations between control subjects and METH users were performed using Student's t tests. Linear regression analyses were performed between GLX concentrations and the total lifetime exposure to METH and the time since last METH exposure (both log transformed). A nonlinear exponential model was also fitted to the GLX data with time as the independent variable, using SAS. Additional linear regression analyses were performed between the change in the GLX concentration over 5 months and the time of abstinence at baseline examination (log transformed). Furthermore, the relationship between GLX concentrations in voxels with significant regressions with the duration of abstinence and two other metabolites in each of these voxels (NA as a neuronal marker and myoinositol as a glial marker) were assessed using linear regressions. Statistical significance was defined as p<0.05.
Results
On average, the METH users had used the drug 5.9±1.7 times per week and for 109±69 months and had stopped using METH 2.1±3.0 months (range=1 week to 12 months) prior to the study. All METH users smoked the drug in its crystalline form. Mean daily estimated METH use was 1.3± 1.2 g (median=1.0 g), and the mean estimated cumulative lifetime exposure was 3,068±2,900 g (median=2,079 g). Although the METH subjects had lower educational attainment than the control subjects (12.4±1.2 vs. 14.8±1.5 years, t 51 =6.3), the average estimated verbal intelligence quotient did not differ between the two groups (METH=98.4±12.1; controls=101.8±11.8, t 51 =1.0).
At baseline, perhaps due to the variation in duration of abstinence, the concentrations of GLX or NA were not significantly different between the METH users and the control subjects in any of the three brain regions studied. However, the time of abstinence (after log transformation) showed a positive correlation with the GLX but not the NA concentration in the frontal gray matter (r=+0.78, p< 0.0001, F 1, 22 =35.1, Fig. 2a ) and the frontal white matter (r=+0.44, p=0.03, F 1, 20 =5.4, Fig. 2b) , and a trend for correlation in the basal ganglia (r=0.37, p=0.09, F 1, 22 = 3.1). Specifically, the GLX concentration was approximately 15% below normal levels in subjects who were within the first 2 weeks of abstinence, reached normal concentrations in subjects who were abstinent for 1-2 months, and exceeded normal levels in subjects with longer-term abstinence (see Fig. 2a,b) . The correlation between the GLX concentration and duration of abstinence
Prefrontal cortex
Basal ganglia Frontal WM Fig. 1 . Location of MRS voxels in frontal cortex, frontal white matter (WM), and basal ganglia remained significant after correction for multiple comparisons (using Bonferroni's method) in the frontal cortex (anterior cingulate). Furthermore, the 16 METH users with less than or equal to 1 month of abstinence showed reduced GLX concentrations in the frontal gray matter (17.1±1.3) compared to control subjects (18.5±1.7 mM; p=0.01, t 41 = 2.6) but not in the basal ganglia or frontal white matter. No correlations were observed between the GLX concentrations in any of the brain regions and the logarithm of cumulative lifetime METH exposure. The linear regression curves shown in Fig. 2 represent a logarithmic relationship between the time of abstinence and the GLX concentration, which is not truly a realistic model, since the GLX concentration cannot increase indefinitely with time. Therefore, we refitted the data with a monoexponential model (with a negative time constant and a positive offset) that represents a gradual initial rise of the GLX concentration with time toward a "steady-state" level over longer time periods. The results of these fits are shown as red curves in the figures. In the frontal gray matter, the best fit reveals a long-term "steady-state" concentration of 21.2 mM, with a 95% confidence interval (CI, 19.4 to 22.9 mM) above the concentration in the control subjects (18.5 mM). The time constant of the initial rise is 2.3 months (95% CI 0.22 to 4.4 months), during which 63% of the initial rise would be completed. The overall increase in frontal gray matter GLX over time was 5.6 mM (95% CI 3.7 to 7.5 mM), which represents a 36% increase over the GLX value during early abstinence. In the basal ganglia, the "steady-state" concentration of GLX was 20.3 mM (CI 16.8 to 23.8 mM), the time constant 1.9 months (CI −3.2 to 6.9 months), and the overall rise 4.0 mM (CI −0.4 to 8.4 mM). In the white matter, the nonlinear fit yielded a steady-state GLX concentration of 12.5 mM (95% CI 11.4 to 13.5 mM) and an overall rise of 10.1 mM; however, the latter value was not significantly different from zero (95% CI −9.0 to 29.3 mM).
Longitudinal changes in GLX concentrations over 5 months If the scenario described in the previous paragraph (based on cross-sectional data from different METH subjects) is correct, then the GLX concentration should (1) increase over time in abstinent METH users with brief periods of abstinence, (2) be relatively unchanged over time in users with intermediate periods of abstinence, and (3) possibly decrease in users with longer periods of abstinence (if in fact there is gradual normalization after the initial phase of overcompensation). Accordingly, longitudinal changes were evaluated in a subgroup (n=12) of these abstinent METH users, in whom follow-up data were available. The subjects were evaluated with 1 H MRS at baseline and again 5 months later, while being monitored weekly at the rehabilitation center to ensure that they remained abstinent. The baseline scan was performed within the first 2 months of abstinence in the majority of subjects (10 of 12). The 12 subjects in this group showed the same effect of time of abstinence (after log transform) on the frontal gray matter GLX ( p=0.003, F 1, 11 =14.6) and basal ganglia GLX ( p=0.005, F 1, 9 =14.9) as the entire METH group. Additionally, there were no significant differences in any of the epidemiological or drug usage variables between subjects with and without a repeat scan, suggesting that the subsample of repeat subjects was representative for the entire METH group. The 5-month change in GLX in the frontal cortex is illustrated in Fig. 3a as 12 individual data pairs. Overall, GLX concentrations increased in subjects who were studied within 1 month of withdrawal and were approximately unchanged in subjects with 1-2 months of abstinence. One subject showed a markedly decreased GLX level after 10 months of abstinence (dark blue line); however, this participant had been abstinent for 5 months already at enrollment but had relapsed and began using METH just days before her repeat scan 5 months later and had a positive urine toxicology screen on the day of the follow-up scan. For the remaining 11 subjects who supposedly did not relapse, 5-month changes in the GLX concentration in the frontal gray matter but not the basal ganglia showed a trend to correlate inversely with the log of duration of abstinence (r=−0.56, p=0.07, F 1, 10 =4,0; Fig. 3b ).
Effects of craving on GLX concentrations and relationship of GLX to other MRS markers
Of the 25 recently abstinent METH-dependent subjects recruited, 15 had symptoms of craving (defined as a craving VAS>0; mean VAS=34±25), and ten had no symptoms of craving for METH (VAS=0) at the time of the baseline study. The prefrontal gray matter GLX concentration was significantly lower (−8%; p=0.05, t 1, 22 =2.1) in subjects who had any craving symptoms compared to subjects without craving for METH. This relationship remained significant when all METH scans (baseline and repeat) were included in the analysis (p=0.025, t 1, 38 =2.3). We also evaluated the relationship between the GLX concentrations and depression scores, but no significant correlations were found.
Furthermore, in the basal ganglia, the GLX concentration was correlated positively with the concentration of NA (a neuronal marker, r=0.47, p=0.03, F 1, 20 =5.3), but not with the glial marker myoinositol. However, the basal ganglia NA concentration showed only a nonsignificant trend for correlation with the duration of abstinence (r= 0.29, p=0.17, F 1, 20 =2.1).
Discussion
To our knowledge, this is the first 1 H MRS study demonstrating abnormal GLX levels in abstinent human METH abusers and their relationship with the time of abstinence. Specifically, the METH users showed reduced GLX during early abstinence, followed by relatively normal GLX concentrations after 1-2 months of abstinence, and possibly some overcompensation in the longer term, especially in the frontal gray matter. The recovery of the GLU system appears to have a typical time constant of 2 months and result in a 30% increase in GLX over the baseline levels. The cross-sectional findings are further supported by longitudinal GLX changes, with the largest 5-month increases in subjects who were initially scanned soon after the cessation of METH use. Together, these results suggest a scenario in which the glutamate/glutamine system is downregulated in METH abusers during early abstinence.
GLU is synthesized de novo from ketoglutarate via the tricarboxylic acid (TCA) cycle. GLU in neurons has the dual roles of an amino acid and that of the most abundant excitatory neurotransmitter. GLU released during synaptic transmission into the extracellular space (ECS) is taken up by astrocytes and converted into glutamine. Astrocytes then release glutamine into the ECS, which is taken up by neurons and converted back into GLU. The flux through this "GLU-glutamine shuttle" represents 40-50% of the total flux from the TCA cycle (Morris and Bachelard 2003; Shen et al. 1999) . One potential explanation for reduced GLX is a loss of glutamatergic neurons. In the basal ganglia, this interpretation has some support due to the positive correlation between GLX and the NA concentration, a putative neuronal marker. Prior MRS studies have consistently documented decreased NA in the frontal gray matter or basal ganglia regions (Ernst et al. 2000; Nordahl et al. 2002) . However, our data and methods do not allow a clear conclusion that there is loss of glutamatergic neurons in either region in the current cohort of subjects.
Several other mechanisms may account for reduced GLX in abstinent METH users. First, reduced GLX might be the result of decreased de novo synthesis via the TCA cycle. In the rodent striatum, the inhibition of mitochondrial function has been found within 2 h after METH administration. This downregulation of the mitochondrial electron transport chain is thought to be related to oxidative stress after METH-induced GLU and dopamine release (Brown and Yamamoto 2003) . If a state of inhibited mitochondrial function persists after multiple exposures to METH, then a reduction in total GLU plus glutamine is plausible, since the de novo ketoglutarate and eventually GLU synthesis would likely be downregulated as well.
Second, net GLU output (incomplete recycling) by the GLU-glutamine shuttle into the vasculature or ECS may reduce the total amount of GLX. In animal studies, METH administration indeed has been associated with reduced glial GLU uptake and/or recycling (Yamamoto and Bankson 2005) . Additionally, METH causes the activation of glial cells (Hess et al. 1990; Pu and Vorhees 1993) , specifically microglia (Asanuma et al. 2003; Escubedo et al. 1998 ), which in turn may lead to the inhibition of GLU uptake (Zou and Crews 2005) and glutamine synthesis (Muscoli et al. 2005) . The inhibition of glial GLU recycling also might increase extracellular GLU and therefore lead to excitotoxicity.
Third, a reduction in GLX might be due to an increased demand for GLU as an amino acid. Continuous cell damage due to METH-induced oxidative stress (Tata and Yamamoto 2007 ) is likely to require increased repair to cell membranes and increased protein synthesis. The latter case would increase the usage of GLU as an amino acid and therefore reduce GLX, since amino acids generally become invisible to magnetic resonance measurements once they are integrated into larger molecules, such as proteins.
We speculate that all three of the above mechanisms contribute to the current finding of reduced GLX. This view is in agreement with a scenario developed by Yamamato et al., in which METH exposure causes excessive release of dopamine and GLU, leading to a feed-forward cycle of inflammation and oxidative stress and associated glial activation and mitochondrial dysfunction. At autopsy, chronic METH users had higher concentrations of two aldehydes indicative of oxidative damage (Fitzmaurice et al. 2006) .
Our human subjects showed GLX abnormalities in the subcortical as well as cortical gray matter, whereas the METH neurotoxicity is essentially limited to the striatum in animals (Stephans and Yamamoto 1996) . However, rodents are typically exposed to METH for relatively short time periods (days to perhaps weeks), while all of the participants in our study had been abusing METH for years or even decades. It seems plausible that chronic METH exposure might eventually cause damage to the frontal cortex, where the density of dopaminergic synapses is lower but that of glutamatergic synapses is relatively high. Prior MRS studies indeed found lower levels of the neuronal marker NA or NA/Cr in both the frontal and striatal brain regions of chronic METH users (Ernst et al. 2000; Chang et al. 2005; Nordahl et al. 2005; Sung et al. 2007) .
Alternatively, chronic overstimulation of frontal areas due to METH abuse may induce a downregulation of the GLU system to reduce excitotoxicity (Ramonet et al. 2004) . Since the neuronal TCA cycle flux is tightly coupled to neuronal stimulation (Patel et al. 2004 ), a persistent downregulation of basal neuronal activity is likely to be associated with a reduction in the TCA cycle flux, which in turn may cause a decrease in the GLX concentration. In fact, withdrawal from self-administered cocaine, another stimulant, in rodents was associated with reduced intracellular GLU concentrations in the nucleus accumbens (Keys et al. 1998) . A downregulated GLU system may also be associated with the common symptoms of craving and particularly depression (Hasler et al. 2007 ). However, regressions between GLX concentrations and depression scores yielded no significant results.
In our study, a downregulated state (neuroadaptation) of the GLU system to attenuate excitotoxicity might have been revealed by the abrupt elimination of chronic METH exposure after the participants became abstinent by enrolling in a treatment program. Such a neuroadaptive state might reverse over the course of months. For instance, an [18 F]fluoro-deoxy-glucose (FDG) PET study of 17 shortterm abstinent METH users (4-7 days of abstinence) found reduced glucose metabolism relative to nondrug users in the anterior cingulate (same as our medial frontal voxel) but increased metabolism in the ventral striatum (close to our basal ganglia voxel; London et al. 2004) . Since the TCA cycle flux and GLU homeostasis are coupled, this PET study provides some support for our finding of reduced GLX, in particular in the frontal gray matter (anterior cingulate). Conversely, another FDG PET study (Volkow et al. 2001c) found that longer-term abstinence (2 weeks and 5 months) in METH users was associated with increases in glucose consumption globally and in several cortical areas but decreases in subcortial regions (Volkow et al. 2001c) .
Another interesting observation is that subjects with symptoms of craving for METH had lower GLX concentrations in the frontal cortex compared to those without craving. In rats, low basal GLU concentrations in the nucleus accumbens were associated with the reinstatement of self-administration of cocaine (Baker et al. 2003) . However, the reinstatement could be prevented by the administration of N-acetylcysteine, which stimulates the cystine/GLU exchanger and increases basal GLU concentrations (Cornish and Kalivas 2000) . Since lower GLX is observed in those with craving, which may contribute to the relapse of psychostimulant abuse, treatment with medications such as N-acetylcysteine might decrease craving and prevent relapse. Decreased cocaine usage and longer retention were observed in a recent open-labeled study of human cocaine users who received N-acetylcysteine (Mardikian et al. 2007 ). However, a clinical trial of N-acetylcysteine for treatment of METH abuse has not been performed and is needed.
Two technical limitations may affect our findings. First, the techniques employed to acquire and analyze the data cannot distinguish GLU from glutamine at a 1.5-T field strength; therefore, our findings may reflect changes in either GLU or glutamine or both. However, as discussed above, several mechanisms in abstinent METH users are likely to decrease GLX, which can be detected by our method. Second, apparent changes in GLX, as measured in this study, might be partly due to changes in lipid or macromolecule signals that coresonate with GLX (Behar et al. 1994) , perhaps due to cell membrane injury associated with METH-induced neurotoxicity. Future studies using techniques to eliminate these macromolecule and lipid signals are needed to validate our observations. We conclude that 1 H MRS provides in vivo evidence for abnormalities in the GLU and glutamine systems of abstinent chronic METH abusers. These findings are consistent with a model of a downregulated glutamatergic state immediately after METH withdrawal and a gradual reversal over longer time periods. However, it is unclear whether changes in GLX after long-term METH use would reverse completely during continued abstinence or whether some of the alterations in GLX would persist. The size of the effect and the noninvasive nature of MRS studies suggest that GLX, measured with 1 H MRS, may be a useful biomarker to study short-term changes in brain metabolism after cessation of METH abuse. Future studies may employ new MRS methods that specifically evaluate GLU (Hurd et al. 2004) or glutamine separately, measure changes longitudinally both at the onset of abstinence and after longer periods (6 to 9 months) of abstinence, and further determine if the severity of the hypoglutamatergic state correlates with craving or withdrawal symptoms. Should these preliminary observations be validated, measurements of GLX or GLU may provide an important surrogate marker for the monitoring of treatment effects in clinical trials or to determine which individuals might need more aggressive treatment approaches, such as adjunctive pharmacotherapy.
